Is	O
Localized	B:C0036420
Scleroderma	I:C0036420
Caused	O
by	O
Borrelia	O
burgdorferi	I:C0006034
?	O

Is	O
Localized	O
Scleroderma	I:C0036420
Caused	O
by	O
Borrelia	B:C0006034
burgdorferi	I:C0006034
?	O

Despite	O
considerable	O
achievements	O
in	O
the	O
study	B:C2603343
of	O
localized	O
scleroderma	I:C0036420
,	O
the	O
etiology	O
of	O
the	O
disease	O
has	O
not	O
been	O
investigated	O
completely	O
.	O

Despite	O
considerable	O
achievements	O
in	O
the	O
study	O
of	O
localized	B:C0036420
scleroderma	I:C0036420
,	O
the	O
etiology	O
of	O
the	O
disease	O
has	O
not	O
been	O
investigated	O
completely	O
.	O

Despite	O
considerable	O
achievements	O
in	O
the	O
study	O
of	O
localized	O
scleroderma	I:C0036420
,	O
the	O
etiology	O
of	O
the	O
disease	B:C0012634
has	O
not	O
been	O
investigated	O
completely	O
.	O

Borrelia	B:C0006034
burgdorferi	I:C0006034
-	O
the	O
agent	O
of	O
Lyme	O
disease	I:C0024198
-	O
is	O
suggested	O
to	O
be	O
one	O
of	O
the	O
possible	O
etiological	O
factors	O
of	O
localized	O
scleroderma	I:C0036420
.	O

Borrelia	O
burgdorferi	I:C0006034
-	O
the	O
agent	O
of	O
Lyme	B:C0024198
disease	I:C0024198
-	O
is	O
suggested	O
to	O
be	O
one	O
of	O
the	O
possible	O
etiological	O
factors	O
of	O
localized	O
scleroderma	I:C0036420
.	O

Borrelia	O
burgdorferi	I:C0006034
-	O
the	O
agent	O
of	O
Lyme	O
disease	I:C0024198
-	O
is	O
suggested	O
to	O
be	O
one	O
of	O
the	O
possible	O
etiological	O
factors	O
of	O
localized	B:C0036420
scleroderma	I:C0036420
.	O

However	O
,	O
among	O
scientists	B:C0402112
,	O
this	O
hypothesis	O
is	O
quite	O
controversial	O
.	O

We	O
have	O
conducted	O
investigations	B:C0220825
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	O
class	O
antibodies	O
to	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	B:C0020861
and	O
IgG	O
class	O
antibodies	O
to	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	B:C0020852
class	O
antibodies	O
to	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	O
class	O
antibodies	B:C0003241
to	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	O
class	O
antibodies	O
to	O
B.	B:C0006034
burgdorferi	I:C0006034
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	O
class	O
antibodies	O
to	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
serum	B:C0229671
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	O
class	O
antibodies	O
to	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	B:C0036420
scleroderma	I:C0036420
.	O

To	O
rationally	O
substantiate	O
the	O
role	O
of	O
B.	B:C0006034
burgdorferi	I:C0006034
in	O
the	O
occurrence	O
of	O
localized	O
scleroderma	I:C0036420
,	O
thirty	O
-	O
two	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
treated	O
at	O
an	O
in	O
-	O
patient	O
department	O
were	O
examined	O
.	O

To	O
rationally	O
substantiate	O
the	O
role	O
of	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
occurrence	O
of	O
localized	B:C0036420
scleroderma	I:C0036420
,	O
thirty	O
-	O
two	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
treated	O
at	O
an	O
in	O
-	O
patient	O
department	O
were	O
examined	O
.	O

To	O
rationally	O
substantiate	O
the	O
role	O
of	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
occurrence	O
of	O
localized	O
scleroderma	I:C0036420
,	O
thirty	O
-	O
two	O
patients	O
with	O
localized	B:C0036420
scleroderma	I:C0036420
treated	O
at	O
an	O
in	O
-	O
patient	O
department	O
were	O
examined	O
.	O

To	O
rationally	O
substantiate	O
the	O
role	O
of	O
B.	O
burgdorferi	I:C0006034
in	O
the	O
occurrence	O
of	O
localized	O
scleroderma	I:C0036420
,	O
thirty	O
-	O
two	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
treated	O
at	O
an	O
in	O
-	O
patient	O
department	B:C1547116
were	O
examined	O
.	O

The	O
level	O
of	O
anti-Borrelia	B:C0003241
antibodies	I:C0003241
was	O
determined	O
in	O
ELISA	O
.	O

The	O
level	O
of	O
anti-Borrelia	O
antibodies	I:C0003241
was	O
determined	O
in	O
ELISA	B:C0014441
.	O

Diagnostic	O
levels	O
of	O
IgM	B:C0020861
and	O
/	O
or	O
IgG	O
were	O
detected	O
in	O
18.8	O
%	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
,	O
which	O
is	O
more	O
than	O
in	O
the	O
population	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Diagnostic	O
levels	O
of	O
IgM	O
and	O
/	O
or	O
IgG	B:C0020852
were	O
detected	O
in	O
18.8	O
%	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
,	O
which	O
is	O
more	O
than	O
in	O
the	O
population	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Diagnostic	O
levels	O
of	O
IgM	O
and	O
/	O
or	O
IgG	O
were	O
detected	O
in	O
18.8	O
%	O
of	O
patients	O
with	O
localized	B:C0036420
scleroderma	I:C0036420
,	O
which	O
is	O
more	O
than	O
in	O
the	O
population	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Diagnostic	O
levels	O
of	O
IgM	O
and	O
/	O
or	O
IgG	O
were	O
detected	O
in	O
18.8	O
%	O
of	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
,	O
which	O
is	O
more	O
than	O
in	O
the	O
population	B:C1257890
(	O
p	O
<	O
0.01	O
)	O
.	O

Positive	B:C1514241
levels	I:C1514241
of	O
anti-Borrelia	O
antibodies	I:C0003241
in	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
confirm	O
the	O
borreliosis	O
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	O
treatment	O
.	O

Positive	O
levels	I:C1514241
of	O
anti-Borrelia	B:C0003241
antibodies	I:C0003241
in	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
confirm	O
the	O
borreliosis	O
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	O
treatment	O
.	O

Positive	O
levels	I:C1514241
of	O
anti-Borrelia	O
antibodies	I:C0003241
in	O
patients	O
with	O
localized	B:C0036420
scleroderma	I:C0036420
confirm	O
the	O
borreliosis	O
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	O
treatment	O
.	O

Positive	O
levels	I:C1514241
of	O
anti-Borrelia	O
antibodies	I:C0003241
in	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
confirm	O
the	O
borreliosis	B:C0006035
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	O
treatment	O
.	O

Positive	O
levels	I:C1514241
of	O
anti-Borrelia	O
antibodies	I:C0003241
in	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
confirm	O
the	O
borreliosis	O
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	B:C1136254
treatment	O
.	O

Positive	O
levels	I:C1514241
of	O
anti-Borrelia	O
antibodies	I:C0003241
in	O
patients	O
with	O
localized	O
scleroderma	I:C0036420
confirm	O
the	O
borreliosis	O
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	O
treatment	B:C0087111
.	O

